Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Trial Profile

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Germ cell and embryonal neoplasms; Malignant melanoma; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Dec 2015 Treatment arms has been increased from 1 to 5 according to ClinicalTrials.gov.
    • 07 Dec 2015 Planned number of patients changed from 60 to 205 as reported by ClinicalTrials.gov.
    • 07 Dec 2015 Planned primary completion date changed from 1 Oct 2013 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top